Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 2011. The report details a specific share repurchase transaction executed on May 23, 2011, authorized by shareholders at the Annual General Meeting held on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share repurchase activity.
- Shares Repurchased: 500,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,321.50 pence per share; lowest price paid was 1,311.50 pence per share.
- Treasury Holdings (Settled): 494,449,284 shares (8.74% of total issued share capital).
- Treasury Holdings (Including Unsettled): 495,699,284 shares (9.60% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,162,079,971 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 500,000 shares for Treasury. This transaction increased the percentage of total voting rights held in Treasury from the prior settled position to 9.60% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase or subscribe for securities.
Investor Verification Checklist
- Verify the total number of shares in issue (5,162,079,971) for calculating disclosure thresholds under FSA rules.
- Confirm the current percentage of voting rights held in Treasury (9.60% including unsettled shares).
- Review the price paid per share (1,311.50 to 1,321.50 pence) against market prices on May 23, 2011.
- Note that this filing does not contain operational or financial performance data for the period.